Omnicare Clinical Research announced today that it has expanded its global footprint to include an office in Sweden.
OMNICARE CLINICAL RESEARCH OPENS OFFICE IN SWEDEN
King of Prussia, PA-11 August 2008-Omnicare Clinical Research announced today that it has expanded its global footprint to include an office in Sweden. The office is located at Kista Science Tower, Unit B1272, Färögatan 33, 164 51 Kista, Sweden.
“Omnicare Clinical Research continues to expand its worldwide presence through the opening of this new Swedish facility,” said Dr. Dale Evans, President and CEO. “We are committed to the Scandinavian marketplace, where we already have offices in Denmark and Finland. We’re looking forward to future growth and continued success with our partners in the region.”
About Omnicare Clinical Research
Headquartered in King of Prussia, PA, Omnicare Clinical Research provides clinical
development services to pharmaceutical, biotechnology and medical device companies through
its office locations in 31 countries worldwide. As a premier Phase I-IV contract research
organization, Omnicare Clinical Research features diverse therapeutic expertise and a
comprehensive scope of clinical service offerings. Additionally, the company is an industry
leader in geriatrics-focused drug studies. Omnicare Clinical Research focuses on providing clients with a superior drug development experience through strong project management, exceptional service and proactive solutions. The company is a subsidiary of Omnicare, Inc., a leading provider of pharmacy services to long-term care facilities and other chronic care settings comprising nearly 1.4 million beds in 47 states (NYSE: OCR).
www.OmnicareCR.com
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.